C. Thieblemont
@c_thieblemont
Followers
737
Following
101
Statuses
68
Lymphoma expert. Université Paris. @APHP @HopSaintLouis, @univ_Paris
Paris, France
Joined August 2017
RT @graham74GC: Dreyling: longer FU of Triangle (55mo) - Signif OS benefit of Ibr containing arms - FFS: ASCT+ibr superior to ASCT - FFS: I…
0
28
0
RT @graham74GC: Thanks Raul. Real pleasure to do this. Great interaction from the audience suggesting a lot of interest in this disease and…
0
1
0
RT @ESHaematology: 📣 #ESHLYMPHOMA2024 PROGRAMME HIGHLIGHT: Rountable 2! To attend it, register here ➡ 4th How to Di…
0
4
0
RT @ComeBommier: Ce 12 juillet, les pilotes de la @PAFofficiel ont laissé leurs alphajets pour venir visiter @HopSaintLouis par le biais de…
0
8
0
RT @gloria_iacoboni: Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CAR T‐cells @Hemasphere…
0
20
0
RT @ComeBommier: Ce soir, le @SFParisRugby joue la demi-finale de Top14. 🏉 C’est un club qui porte ses valeurs dans la ville de Paris en s…
0
1
0
RT @graham74GC: Bories - CAR-T in 75y+ (Descar-T data) - ORR, PFS & OS all similar in older pts - NRM higher in 75+, main cause infection -…
0
14
0
RT @graham74GC: Stephan - outcome of transf iNHL with CAR-T (Descar-T data) - propensity score matching - compared with de novo DLBCL - Bet…
0
11
0
RT @lymphomahub: CONGRESS | #EHA2024 Jean Galtier @CHUBordeaux reports on 55 patients with R/R PMBCL treated with axi-cel in the French DES…
0
5
0
RT @graham74GC: Galtier - outcome of PMBCL with CAR-T (Descar-T data) - 55 axi-cel pts - 80% CMR - 2y PFS 68.7% - CRP > 30 prognostic - LDH…
0
16
0
RT @ComeBommier: @HopSaintLouis DEPHI / IRSL est super fier d’accueillir Michel Sadelain pour: « Antigen sensitivity, logic gating and per…
0
4
0
RT @ComeBommier: Café de 8h30 à @HopSaintLouis. Dans celui-ci, on y trouve: - 15 prescriptions - 6 chimiothérapies - 4 thérapies innovant…
0
1
0
Fantastic 2-day discussion on new strategies in DLBCL with colleagues and friends from Brazil! @HopSaintLouis @CancerParisNord @univ_paris_cite
0
2
39
RT @Eddie_Cliff: What clinicians should know about surrogate endpoints Nice work @ComeBommier @MaurerStats Many great examples woven int…
0
20
0
RT @ComeBommier: Merci au @SFParisRugby pour sa promotion du sport santé et son implication à nos côtés ! Un coup de main plus que bienve…
0
7
0
1
0
1
PhD thesis today @ComeBommier discussing about MZL, surrogacy, endpoints. Strong collaboration with Mayo Clinic, Congratulations !
5
3
40
RT @lymphomahub: CONGRESS | #CART24 | @Roberta04704608 @HopSaintLouis discusses intensive care management strategies with CAR T-cell thera…
0
12
0
RT @ComeBommier: It is such a challenge to set up P3 trials in extranodal MZL!🙁 By diminishing the follow up duration to 2 years only💪, we…
0
2
0
RT @ComeBommier: Célébrez Noël 🎅🏼 en offrant les meilleurs équipements d’activité physique adaptée pour les patients atteints de lymphome!…
0
12
0